Rudolf Hoermann

Rudolf Hoermann

Auto-generated profile, based on publicly available information

Rudolf Hoermann

Retired] Klinikum Lüdenscheid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
MSMarie Sinclair
Marie Sinclair
MGMathis Grossmann
Mathis Grossmann
RHRudolf Hoermann
Rudolf Hoermann
PAPeter W. Angus
Peter W. Angus
PGPaul J. Gow
Paul J. Gow

1 July 1996 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
MWMartin K. Walz
Martin K. Walz
KPKlaus Peitgen
Klaus Peitgen
RHRudolf Hoermann
Rudolf Hoermann
RGReiner M. Giebler
Reiner M. Giebler
KMKlaus Mann
Klaus Mann
FEFriedrich W. Eigler
Friedrich W. Eigler

20 July 2017 in Frontiers in Endocrinology
Verified
Journal Article
Open access
ACApostolos Chatzitomaris
Apostolos Chatzitomaris
RHRudolf Hoermann
Rudolf Hoermann
JMJohn E. Midgley
John E. Midgley
SHSteffen Hering
Steffen Hering
AUAline Urban
Aline Urban
Johannes W. DietrichJohannes W. Dietrich
Johannes W. Dietrich
The hypothalamus-pituitary-thyroid feedback control is a dynamic, adaptive system. In situations of illness and deprivation of energy representing type 1 allostasis, the stress response operates to alter both its set point and peripheral transfer parameters. In contrast, type 2 allostatic load, typically effective in psychosocial stress, pregnancy, metabolic syndrome and adaptation to cold, produces a nearly opposite phenotype of predictive plasticity. The non-thyroidal illness syndrome (NTIS) or thyroid allostasis in critical illness, tumours, uraemia and starvation (TACITUS), commonly observed in hospitalised patients, displays a historically well-studied pattern of allostatic thyroid response. This is characterised by decreased total and free thyroid hormone concentrations and varying levels of thyroid-stimulating hormone (TSH) ranging from decreased (in severe cases) to normal or even elevated (mainly in the recovery phase) TSH concentrations. An acute versus chronic stage (wasting syndrome) of TACITUS can be discerned. The two types differ in molecular mechanisms and prognosis. The acute adaptation of thyroid hormone metabolism to critical illness may prove beneficial to the organism, whereas the far more complex molecular alterations associated with chronic illness frequently lead to allostatic overload. The latter is associated with poor outcome, independently of the underlying disease. Adaptive responses of thyroid homeostasis extend to alterations in thyroid hormone concentrations during fetal life, periods of weight gain or loss, thermoregulation, physical exercise and psychiatric diseases. The various forms of thyroid allostasis pose serious problems in differential diagnosis of thyroid disease. This review article provides an overview of physiological mechanisms as well as major diagnostic and therapeutic implications of thyroid allostasis under a variety of developmental and straining conditions.

9 June 2016 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
Johannes W. DietrichJohannes W. Dietrich
Johannes W. Dietrich
GLGabi Landgrafe-Mende
Gabi Landgrafe-Mende
EWEvelin Wiora
Evelin Wiora
ACApostolos Chatzitomaris
Apostolos Chatzitomaris
HKHarald H. Klein
Harald H. Klein
RHRudolf Hoermann
Rudolf Hoermann
Although technical problems of thyroid testing have largely been resolved by modern assay technology, biological variation remains a challenge. This applies to subclinical thyroid disease, non-thyroidal illness syndrome and those 10% of hypothyroid patients, who report impaired quality of life despite normal thyrotropin (TSH) concentrations under L-T4 replacement. Among multiple explanations for this condition inadequate treatment dosage and monotherapy with L-T4 in subjects with impaired deiodination have received major attention. Translation to clinical practice is difficult, however, since univariate reference ranges for TSH and thyroid hormones fail to deliver robust decision algorithms for therapeutic interventions in patients with more subtle thyroid dysfunctions. Advances in mathematical and simulative modelling of pituitary-thyroid feedback control have improved our understanding of physiological mechanisms governing the homeostatic behaviour. From multiple cybernetic models developed since 1956, four examples have also been translated to applications in medical decision-making and clinical trials. Structure parameters representing fundamental properties of the processing structure include the calculated secretory capacity of the thyroid gland (SPINA-GT), sum activity of peripheral deiodinases (SPINA-GD), Jostel’s TSH index for assessment of thyrotropic pituitary function and a recently published algorithm for reconstructing the personal set point of thyroid homeostasis. In addition, a family of integrated models (UCLA platform) provides advanced methods for bioequivalence studies. This perspective article delivers an overview of current clinical research on the basis of mathematical thyroid models. In addition to a summary of large clinical trials it provides previously unpublished results of validation studies based on simulation and clinical samples.

1 June 2003 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
AEA Eckstein
A Eckstein
BQB Quadbeck
B Quadbeck
GMG Mueller
G Mueller
ARA W Rettenmeier
A W Rettenmeier
RHR Hoermann
R Hoermann
JEJ Esser
J Esser
Background: In patients with Graves’ disease, smoking considerably increases the incidence and severity of thyroid associated ophthalmopathy (TAO). The authors sought to determine if smoking also influences the course of TAO during treatment, and the efficacy of therapy. Methods: 41 smokers and 19 non-smokers with moderate untreated TAO were included in this prospective study. All patients were treated with steroids and, 6 weeks after the beginning of drug therapy, with orbital irradiation. Follow up was performed 1.5, 4.5, 7.5, and 12 months after the beginning of the study. Proptosis, clinical activity score (CAS), and motility were evaluated. The extent of smoking was derived from the concentration of the haemoglobin adduct N-2-hydroxyethylvaline (HEV), a parameter of long term smoking. Results: There was no difference in the clinical manifestations of TAO between smokers and non-smokers at the beginning of treatment. However, CAS decreased (p<0.05) and motility improved (p<0.02) significantly faster and to a greater extent in non-smokers than smokers. Inverse correlations between the CAS decrease and the HEV levels observed 4.5 and 7.5 months after the beginning of treatment and between the improvement of motility and the HEV levels after 1.5, 4.5, and 7.5 months indicated a dose dependence. Mean HEV levels did not vary much during the follow up period and were significantly different in smokers (mean 5.4 (SD 2.7) μg/l) and non-smokers (mean 1.8 (1.3) μg/l; p<0.01). Conclusion: Smoking influences the course of TAO during treatment in a dose dependent manner. The response to treatment is delayed and considerably poorer in smokers.

12 July 2014 in Diabetes Care
Verified
Journal Article
Open access
PDF file
EGEmily J. Gianatti
Emily J. Gianatti
PDPhilippe Dupuis
Philippe Dupuis
RHRudolf Hoermann
Rudolf Hoermann
BSBoyd J. Strauss
Boyd J. Strauss
JWJohn M. Wentworth
John M. Wentworth
MGMathis Grossmann
Mathis Grossmann
OBJECTIVE To determine whether testosterone therapy improves glucose metabolism in men with type 2 diabetes (T2D) and lowered testosterone. RESEARCH DESIGN AND METHODS We conducted a randomized, double-blind, parallel, placebo-controlled trial in 88 men with T2D, aged 35–70 years with an HbA1c ≤8.5% (69 mmol/mol), and a total testosterone level, measured by immunoassay, of ≤12.0 nmol/L (346 ng/dL). Participants were randomly assigned to 40 weeks of intramuscular testosterone undecanoate (n = 45) or matching placebo (n = 43). All study subjects were included in the primary analysis. Seven men assigned to testosterone and six men receiving placebo did not complete the study. Main outcome measures were insulin resistance by homeostatic model assessment (HOMA-IR, primary outcome) and glycemic control by HbA1c (secondary outcome). RESULTS Testosterone therapy did not improve insulin resistance (mean adjusted difference [MAD] for HOMA-IR compared with placebo −0.08 [95% CI −0.31 to 0.47; P = 0.23]) or glycemic control (MAD HbA1c 0.36% [0.0–0.7]; P = 0.05), despite a decrease in fat mass (MAD −2.38 kg [−3.10 to −1.66]; P < 0.001) and an increase in lean mass (MAD 2.08 kg [1.52–2.64]; P < 0.001). Testosterone therapy reduced subcutaneous (MAD −320 cm3 [−477 to −163]; P < 0.001) but not visceral abdominal adipose tissue (MAD 140 cm3 [−89 to 369]; P = 0.90). CONCLUSIONS Testosterone therapy does not improve glucose metabolism or visceral adiposity in obese men with moderately controlled T2D and modest reductions in circulating testosterone levels typical for men with T2D.